ESPR
Esperion Therapeutics, Inc.
NASDAQ · USHealthcareDrug Manufacturers - Specialty & Generic
$3.18+0.00%
Price as of Jul 14, 2026
ESPR financials
Esperion Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $403.1M | $332.3M | $116.3M | $75.5M |
| Cost of revenue | $129.2M | $68.6M | $43.3M | $27.0M |
| Gross profit | $273.9M | $263.7M | $73.1M | $48.5M |
| Operating expenses | $213.6M | $209.3M | $228.6M | $228.0M |
| Operating income | $60.3M | $54.4M | -$155.6M | -$179.5M |
| Net income | -$22.7M | -$51.7M | -$209.2M | -$233.7M |
| EBITDA | $63.9M | $7.6M | -$150.1M | -$176.3M |
| Basic EPS | $-0.11 | $-0.28 | $-2.03 | $-4.33 |
| Diluted EPS | $-0.11 | $-0.28 | $-2.03 | $-4.33 |
| Balance sheet | ||||
| Cash & equivalents | $167.9M | $144.8M | $82.2M | $124.8M |
| Total assets | $465.9M | $343.8M | $205.8M | $247.9M |
| Total liabilities | $767.9M | $732.5M | $660.8M | $571.7M |
| Stockholders’ equity | -$302.0M | -$388.7M | -$455.0M | -$323.8M |
| Total debt | $548.0M | $591.2M | $540.9M | $260.9M |
| Net debt | $380.1M | $446.5M | $458.7M | $136.2M |
| Cash flow | ||||
| Operating cash flow | -$13.1M | -$23.7M | -$135.5M | -$174.8M |
| Capital expenditure | $0.00 | -$317.0K | $0.00 | $0.00 |
| Free cash flow | -$13.1M | -$24.0M | -$135.5M | -$174.8M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |